INShore: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome (clinicaltrials.gov) - Oct 15, 2026 - P3 | N=85 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed
Trial completion • Glomerulonephritis • Nephrology • Renal Disease
|